CR

Caribou Biosciences Reports Second Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, August 8, 2023
Exercise, Rachel Haurwitz, Maintenance, CRISPR, Doctor of Philosophy, Acute myeloid leukemia, AML, Patent, Patient, MM, CR, Research, FDA, IND, ORR, Pharmaceutical industry, Security (finance), Fine chemical, Vaccine, Bookkeeping, Reindeer, Pfizer

-- Closed upsized public offering including full exercise of underwriters’ option to purchase additional shares, delivering $134.6 million in net proceeds --

Key Points: 
  • As of the June 20, 2023 data cutoff date, results demonstrated:
    CB-010 was generally well tolerated with adverse events consistent with autologous and allogeneic anti-CD19 CAR-T cell therapies.
  • $25.0 million Pfizer investment: On June 30, 2023, Pfizer invested $25.0 million in Caribou common shares.
  • This amount does not include the approximately $134.6 million in net proceeds from the Company’s underwritten public offering completed in the third quarter of 2023.
  • Net loss: Caribou reported a net loss of $29.5 million for the three months ended June 30, 2023, compared to $26.7 million for the same period in 2022.

Meet cari™: the Generative AI Solution from the Leader in Autism and IDD Care Software

Retrieved on: 
Tuesday, August 8, 2023
ABA, Hallucination, Plague, Autism spectrum, LLM, Hotel Monteleone, BCBA, Mentorship, Organization, IDD, RBT, HIPAA, Spectrum, CR, AI, Environment, Conference, Medical device

FORT LAUDERDALE, Fla., Aug. 08, 2023 (GLOBE NEWSWIRE) -- CentralReach , the leading provider of autism and IDD care software, today announced the generative AI solution designed for autism and IDD care: cariTM.

Key Points: 
  • FORT LAUDERDALE, Fla., Aug. 08, 2023 (GLOBE NEWSWIRE) -- CentralReach , the leading provider of autism and IDD care software, today announced the generative AI solution designed for autism and IDD care: cariTM.
  • A large majority of [time] on our end is [spent] answering questions as someone navigates the 40-hour [course].
  • “Generative AI holds promise as a tool to help automate time-consuming back office and clinical tasks but will be ineffective if training is done on subscale or generic data sets.
  • I can't wait to formally introduce cari to our customers this fall.”
    cari will be unveiled at CR Unite 2023, the Autism and IDD Care Conference, happening October 16th-19th at the Hotel Monteleone in New Orleans.

Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2023 Financial Results

Retrieved on: 
Tuesday, August 8, 2023
Call, Total, TCL, PRS, ALC, BioRxiv, RCC, Neoplasm, KCRC, ITK, Lymphoma, Clinical trial, Extranodal NK/T-cell lymphoma, nasal type, Head, ICB, NSCLC, Cell, Lung cancer, Time management, Preprint, Colon, ATM, American Association for Cancer Research, International Conference on Afghanistan, London (2010), Japanese Cancer Association, Patient, Ipilimumab, Melanoma, Blood, Cancer, Kidney cancer, CR, Webcast, Research, FDA, Pembrolizumab, PR, Safety, Nivolumab, Communications satellite, Pharmaceutical industry, Cryptocurrency, Corvus, Conference

BURLINGAME, Calif., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the second quarter ended June 30, 2023.

Key Points: 
  • ET / 1:30 p.m. PT
    BURLINGAME, Calif., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the second quarter ended June 30, 2023.
  • The latest data from the trial was reported at the International Conference on Malignant Lymphoma, which took place June 13-17, 2023 in Lugano, Switzerland.
  • Based on its current plans, Corvus expects its cash to fund operations into the second half of 2024.
  • ET (1:30 p.m. PT), during which time management will provide a business update and discuss the second quarter 2023 financial results.

Syros Reports Second Quarter 2023 Financial Results and Provides a Corporate Update

Retrieved on: 
Tuesday, August 8, 2023
Biometrics, Health, Pharmaceutical, Clinical Trials, Oncology, PDAC, APL, Completeness, Venetoclax, CDK7, Incyte, ID, RARA, ASCO, HR, AML, Azacitidine, Patient, Annual general meeting, CR, Webcast, Bone marrow, Research, Society, American Society of Clinical Oncology, Pfizer, Pharmaceutical industry, Medical imaging, Syros

Revenues were $2.8 million for the second quarter of 2023, consisting entirely of revenue recognized under Syros’ collaboration with Pfizer.

Key Points: 
  • Revenues were $2.8 million for the second quarter of 2023, consisting entirely of revenue recognized under Syros’ collaboration with Pfizer.
  • Research and development expenses were $29.6 million for the second quarter of 2023, as compared to $33.1 million for the second quarter of 2022.
  • General and administrative expenses were $7.2 million for the second quarter of 2023, as compared to $6.9 million for the second quarter of 2022.
  • ET to discuss these second quarter 2023 financial results and provide a corporate update.

Kura Oncology Reports Second Quarter 2023 Financial Results

Retrieved on: 
Thursday, August 3, 2023
European Hematology Association, Head, CRH, Cancer, Kura, ID, Acute myeloid leukemia, PI3K, Congress, AML, Investigational New Drug, Investment, Patient, KURA, EHA, HNSCC, CR, FLT3, Webcast, Toxic leukoencephalopathy, Research, FDA, Health, Safety, FTI, Disease, Pharmaceutical industry, Video game, Cryptocurrency

ET –

Key Points: 
  • ET –
    SAN DIEGO, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today reported second quarter 2023 financial results and provided a corporate update.
  • Research and development expenses for the second quarter of 2023 were $28.2 million, compared to $24.3 million for the second quarter of 2022.
  • General and administrative expenses for the second quarter of 2023 were $11.8 million, compared to $11.1 million for the second quarter of 2022.
  • ET / 1:30 p.m. PT today, August 3, 2023, to discuss the financial results for the second quarter 2023 and to provide a corporate update.

Protara Therapeutics Announces Second Quarter 2023 Financial Results and Business Update

Retrieved on: 
Thursday, August 3, 2023
Parenteral nutrition, Carcinoma in situ, LMS, Cancer, CIS, BCG, Incidence, Choline, Macrocyst, Patient, Investment, Protaras, CR, Bacillus, Diagnosis, Rare, Research, FDA, Therapy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Pharmaceutical industry, Life insurance, NMIBC

Research and development expenses for the second quarter of 2023 increased to $7.2 million from $3.1 million during the second quarter of 2022, primarily reflecting an increase in expenses related to clinical and non-clinical trial activities for TARA-002.

Key Points: 
  • Research and development expenses for the second quarter of 2023 increased to $7.2 million from $3.1 million during the second quarter of 2022, primarily reflecting an increase in expenses related to clinical and non-clinical trial activities for TARA-002.
  • General and administrative expenses for the second quarter of 2023 decreased to $4.9 million from $5.6 million for the prior year period, primarily due to lower employee related expenses.
  • For the second quarter of 2023, Protara reported a net loss of $11.3 million, or $1.00 per share, compared with a net loss of $8.5 million, or $0.76 per share, for the same period in 2022.
  • Net loss for the second quarter of 2023 included approximately $1.6 million of stock-based compensation expenses.

SENTINEL MEDICAL TECHNOLOGIES ADDRESSES IAP TRANSDUCER SHORTAGE WITH TRAUMAGUARD

Retrieved on: 
Wednesday, August 2, 2023
Sentinel, Centurion, Database, Abdomen, Face, IAH, Workflow, EMR, Abdominal compartment syndrome, OR, DO, Patient, ACS, Patient safety, Risk, Hurley Medical Center, Nursing, CR, IAP, Nursing care plan, ICU, FDA, Health, Human, Medical device, Pharmaceutical industry

JACKSONVILLE, Fla., Aug. 2, 2023 /PRNewswire/ -- In the face of the ongoing supply issues affecting Intra-Abdominal Pressure (IAP) transducer kits, Sentinel Medical Technologies is stepping up to ensure that patient care remains uncompromised.

Key Points: 
  • JACKSONVILLE, Fla., Aug. 2, 2023 /PRNewswire/ -- In the face of the ongoing supply issues affecting Intra-Abdominal Pressure (IAP) transducer kits, Sentinel Medical Technologies is stepping up to ensure that patient care remains uncompromised.
  • The company's FDA-cleared product, TraumaGuard, is now readily available to fill the gap left by the shortage of CR BARD or Centurion IAP kits.
  • Given the critical importance of IAP measurements, the ongoing shortage of transducer kits has created obstacles for healthcare providers, increasing the barriers in delivering essential, life-saving care.
  • Sentinel Medical Technologies is committed to ensuring the availability of TraumaGuard now and in the future.

CentralReach Deepens its Integrated Special Education Offering through Rebrand and Relaunch of CR LiftEd™, its Award-Winning Special Education Data Collection and IEP Management Software Solution

Retrieved on: 
Thursday, July 27, 2023
ABA, Learning, Education, Software, Parent, Teaching, Data collection, BCBA, MBA, IDD, Student, Acquisition, Sibling, Special education, Special needs, CR, IEP, System, Caregiver, Nursing, Management, Autism spectrum

FORT LAUDERDALE, Fla., July 27, 2023 (GLOBE NEWSWIRE) -- CentralReach , the leading provider of Autism and IDD care software, today announced the rebrand and relaunch of its special education data collection and IEP management software, CR LiftEd, formerly LiftEd by CentralReach.

Key Points: 
  • FORT LAUDERDALE, Fla., July 27, 2023 (GLOBE NEWSWIRE) -- CentralReach , the leading provider of Autism and IDD care software, today announced the rebrand and relaunch of its special education data collection and IEP management software, CR LiftEd, formerly LiftEd by CentralReach.
  • CR LiftEd is built for special educators, board-certified behavior analysts (BCBAs), therapists, and administrators to measurably improve teaching and learning outcomes for students with learning disabilities.
  • Founded by siblings Joanne Hill Powell, Ph.D., BCBA-D, and Andrew C. Hill, MBA, CR LiftEd was acquired by CentralReach in 2022 with both founders joining the CentralReach team.
  • To learn more about how CR LiftEd is simplifying and elevating behavioral data collection to empower education and support learner outcomes, visit: edu.centralreach.com/products/lifted

Crane Company Reports Second Quarter 2023 Results and Raises Full Year EPS Guidance

Retrieved on: 
Tuesday, July 25, 2023
Technology, Other Defense, Semiconductor, Engineering, Chemicals, Plastics, Aerospace, Manufacturing, Government Technology, Hardware, Defense, CR, Growth, EPS, Optimism, Acquisition, GAAP, Crane Holdings, Attention, NYSE, Crane, Retail

Crane Company ("Crane," NYSE: CR) today announced its financial results for the second quarter of 2023 and updated its full-year outlook.

Key Points: 
  • Crane Company ("Crane," NYSE: CR) today announced its financial results for the second quarter of 2023 and updated its full-year outlook.
  • Max Mitchell, Crane's President and Chief Executive Officer, stated: “Crane delivered another impressive quarter, its first as a newly independent company following completion of our April 2023 separation transaction.
  • Notably, adjusted operating margins were at or above 20% in both of our strategic growth platforms."
  • Second quarter 2023 GAAP earnings from continuing operations per diluted share (EPS) was $0.75, and adjusted EPS was $1.10.

BMF-219 Induces Complete Responses in Target Acute Myeloid Leukemia (AML) Patient Population

Retrieved on: 
Monday, July 24, 2023
NPM1, Acute leukemia, CYP3A4, NUP98, AML, MD, Patient, DSM-IV codes, Cancer, CR, CRS, Pharmaceutical industry

These relapsed/refractory patients had a range of prior therapies (1 to 8) and two complete responses (1 CR, 1 CRi) were observed within the first two 28-day treatment cycles with BMF-219.

Key Points: 
  • These relapsed/refractory patients had a range of prior therapies (1 to 8) and two complete responses (1 CR, 1 CRi) were observed within the first two 28-day treatment cycles with BMF-219.
  • Enrollment for Dose Level 5 has commenced to further optimize and explore the potential to improve upon these preliminary results.
  • Completion of the dose escalation for the acute leukemia cohort is anticipated later this year.
  • We are continuing to dose escalate and are looking forward to identifying the recommended Phase 2 dose within the next several months.”